TABLE 1.

Baseline Patient Characteristics

CharacteristicData
No. of patients301
Age (y), n = 30173 (67–77)
PSA (ng/mL), n = 29799.5 (20.4–290.3)
LDH (U/L), n = 297263.5 (218–344)
AP (U/L), n = 297112 (72–231)
Hemoglobin (g/dL), n = 29711.7 (10.3–12.8)
Prior systemic therapies for mCRPC, n = 301
 Docetaxel213
 Cabazitaxel48
 Abiraterone252
 Enzalutamide183
223Ra41
 Previous chemotherapy214
No. of prior mCRPC therapies, n = 301
 1105
 2109
 368
 418
 54
Site of metastasis, n = 301
 Lymph node, overall216
 Lymph node only (N1+/M1a)22
 Bone overall274
 Bone (M1b, without visceral metastases)215
 Visceral, overall (M1c)64
 Liver26
 Lung31
 Adrenal21
  • Qualitative data are number and percentage; continuous data are median and interquartile range.